Literature DB >> 30292476

Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study.

Lucia Parlati1, Anais Vallet-Pichard2, Rui Batista3, Alain Hernvann4, Philippe Sogni5, Stanislas Pol5, Vincent Mallet6.   

Abstract

Entities:  

Keywords:  Drug-induced liver injury; Immune checkpoint inhibitor; Observational study

Mesh：

Year:  2018        PMID： 30292476     DOI： 10.1016/j.jhep.2018.08.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  10 in total

1.  New treatment-induced adverse effects we need to learn as modern hepatologists.

Authors:  Yoshiyuki Ueno
Journal:  Hepatol Int       Date:  2019-04-23       Impact factor: 6.047

Review 2.  Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.

Authors:  Julian Hercun; Catherine Vincent; Marc Bilodeau; Pascal Lapierre
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

3.  Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States.

Authors:  Christopher Kim; Shao Zhu; Hosein Kouros-Mehr; Sophia Khaldoyanidi
Journal:  Cureus       Date:  2022-04-11

4.  Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis.

Authors:  Jianyang Fu; Wang-Zhong Li; Nicole A McGrath; Chunwei Walter Lai; Gagandeep Brar; Yan-Qun Xiang; Changqing Xie
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

Review 5.  Mechanisms of immune checkpoint inhibitor-mediated liver injury.

Authors:  Layla Shojaie; Myra Ali; Andrea Iorga; Lily Dara
Journal:  Acta Pharm Sin B       Date:  2021-10-16       Impact factor: 11.413

Review 6.  Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review.

Authors:  Einar S Björnsson; Vesna Vucic; Guido Stirnimann; Mercedes Robles-Díaz
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

7.  Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature.

Authors:  You-Wen Tan; Li Chen; Xing-Bei Zhou
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

Review 8.  Liver damage related to immune checkpoint inhibitors.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Int       Date:  2019-01-03       Impact factor: 9.029

9.  Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.

Authors:  Matthew K Smith; Yin Chan; Aleksi E Suo; Abdel Aziz Shaheen; Stephen E Congly; Puneeta Tandon; Rahima A Bhanji; Malcolm M Wells; Tina Cheng; Christopher Ma
Journal:  J Can Assoc Gastroenterol       Date:  2021-07-28

10.  Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.

Authors:  Masaki Takinami; Akira Ono; Takanori Kawabata; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Masahiro Endo; Yoshio Kiyohara; Hirofumi Yasui; Masashi Niwakawa; Toshiaki Takahashi
Journal:  Invest New Drugs       Date:  2021-05-28       Impact factor: 3.850
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.